G1 Therapeutics

+$0.55 (+11.60%) Today
+$0.21 (+3.97%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GTHX and other ETFs, options, and stocks.

About GTHX

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib.

CEO
Jack Bailey
Employees
148
Headquarters
Research Triangle Park, North Carolina
Founded
2008

GTHX Key Statistics

Market cap
225.91M
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.08M
High today
$5.31
Low today
$4.65
Open price
$4.74
Volume
922.80K
52 Week high
$24.12
52 Week low
$4.25

GTHX News

Simply Wall StMay 24

Following a 77% decline over last year, recent gains may please G1 Therapeutics, Inc. institutional owners - Simply Wall St

To get a sense of who is truly in control of G1 Therapeutics, Inc. ( ), it is important to understand the ownership structure of the business. With 61% stake, i

GTHX Earnings

-$1.15
-$0.77
-$0.38
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 3, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure